Trial · NCT00836693
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12 | Baseline, Week 12 | The efficacy analysis of the three primary efficacy variables (IIEF-EF, SEP Question 2, and SEP Question 3) was performed on all randomized subjects who had at least one baseline and one post-baseline observation on all three variables. | units on a scale | MEAN |
| PRIMARY | Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses | Baseline, Week 12 | The efficacy analysis of the three primary efficacy variables (IIEF-EF, SEP Question 2, and SEP Question 3) was performed on all randomized subjects who had at least one baseline and one post-baseline observation on all three variables. | percentage of yes responses | MEAN |
| PRIMARY | Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses | Baseline, 12 weeks | The efficacy analysis of the three primary efficacy variables (IIEF-EF, SEP Question 2, and SEP Question 3) was performed on all randomized subjects who had at least one baseline and one post-baseline observation on all three variables. | percentage of yes responses | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | Number of events per night | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | minutes | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | percent of volumetric change | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | percent | MEAN |
| SECONDARY | The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint | Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF) | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD) | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS) | Baseline, Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS) | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | units on a scale | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of Yes Responses | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | percentage of yes responses | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of Yes Responses | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | percentage of yes responses | MEAN |
| SECONDARY | Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of Yes Responses | Baseline, 12 weeks | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | percentage of yes responses | MEAN |
| SECONDARY | Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint | Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | participants | NUMBER |
| SECONDARY | Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint | Week 12 | The ITT analysis set included all randomized subjects who had a baseline and post-baseline observation. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00836693/outcomes